Changes from resolution motion to adopted text

23. Recalls the international binding obligations under the Convention on Biological Diversity and its Nagoya Protocol for fair and equitable benefit sharing with regard to genetic materials;

24. Calls on the Commission and the Member States, in line with the objectives of the GHRI, to boost investment in health, education and skills, in particular by strengthening the training, recruitment, retention and fair remuneration of health workers in partner countries and through measures to mitigate the negative effects of international health workforce migration, such as brain drain, as well as research to generate local jobs, support local business development and strengthen resilient health systems;

25. Emphasises that research, higher education and academic partnerships are core components of resilient health systems; calls on the Commission to ensure that EU global health investments systematically support local research institutions, public health schools, regulatory science, workforce training, evidence generation and research-to-policy capacities in partner countries; underlines that prioritising local research and development is essential for tailoring interventions to the specific health needs of low- and middle-income countries where health issues may differ significantly from those in higher-income countries;

26. Calls on the Commission to consider greater geographical flexibility for global health research cooperation, including by enabling stronger participation of partner countries beyond existing regional mandates, where relevant;

27. Believes that appropriate conditionalities should be attached to public funding, notably in terms of transparency, fair governance and the sharing of technical know-how and clinical results, in a manner that strengthens local ownership, accountability and long-term sustainability;

28. Calls on the Commission and the Member States to support the diversification of global supply chains for health technologies through coordinated investments, guarantees, blended finance and public-private partnerships in partner countries; recalls that the COVID-19 pandemic demonstrated the need to reduce excessive dependencies on long, fragile global supply chains and on single suppliers for critical medical equipment and pharmaceuticals; stresses that diversifying and, where appropriate, shortening these supply chains would enhance both partner countries’ resilience and European health security; calls on the Commission to support global pooled procurement and equitable access mechanisms for vaccines, diagnostics, therapeutics and other essential health technologies, drawing lessons from COVAX and ensuring that future emergency responses avoid fragmentation, export restrictions and national self-protection that undermine global preparedness;

29. Calls on the Commission and the Member States, building on the experience gained from Team Europe’s initiative on manufacturing and access to vaccines, medicines and health technologies, to expand support for the sustainable development of local and regional manufacturing capacities for vaccines, therapeutics, diagnostics and other essential health technologies in partner countries, through technology transfer, regulatory guidance, information sharing and investment, including through small and medium-sized enterprises, with a view to strengthening local value chains, reducing dependencies and improving equitable and affordable access to these technologies;

30. Calls for greater transparency regarding public funding of pharmaceutical research and development, including transparency on production costs, clinical trial data and pricing mechanisms, in order to strengthen evidence-based policymaking, public trust and equitable access to health technologies;

31. Calls for the EU and its Member States to enhance coordination on global health by strengthening the operationalisation of the Team Europe approach, including through joint programming, joint implementation and regular mapping of EU and Member States’ investments, in order to improve coherence, complementarity, transparency, accountability, visibility and impact; calls on the Commission to strengthen coordination between partner country health strategies, Team Europe initiatives and Global Gateway in order to maximise development impact and country ownership;

32. Recognises that environmental factors, including pollution, can have a significant impact on health outcomes and development progress in partner countries; encourages the EU, in line with the GHRI’s objective of supporting resilient, country-led health systems, to take into account environmental determinants of health when designing and implementing development cooperation programmes in partner countries;

33. Calls for the EU to assist developing countries, notably low- and middle-income countries and least developed countries, in prioritising disease prevention through investment in the management of pollution, including with strategies on access to clean energy, clean and efficient transport, control of industrial emissions and the sound use of chemicals, as this is a highly cost-effective approach for enhancing population health, easing the pressure on limited health resources and advancing national development;

Supporting global cooperation and multilateralism

34. Reaffirms its strong support for effective multilateralism, with the WHO at its centre, to close the current gaps in global health resilience; underlines that the EU should continue to act as a reliable, long-term partner in addressing global health challenges; calls for the EU to increase its political and financial support to multilateral organisations such as the WHO, Gavi (the Vaccine Alliance), the Global Fund and CEPI; stresses that international organisations should be subject to robust transparency, effectiveness and accountability standards;

35. Stresses that global health resilience requires strong national health systems and effective international cooperation, including through a properly financed and operationally capable WHO that can deliver on its objectives, within its areas of competence; supports the WHO reform process and ongoing efforts to reform the international health architecture; recalls that the protection and improvement of human health is a Member State competence, in line with Article 6 of the Treaty on the Functioning of the European Union, which the EU can support, coordinate or supplement through its actions at EU level; calls for the EU and its Member States to contribute to enhancing the WHO’s effectiveness, transparency and accountability; calls for the EU to strengthen its role in global health governance, particularly by driving forward the work of the UN High-Level Meeting on Non-Communicable Diseases;

36. Calls on the Commission to strengthen cooperation with multilateral organisations, regional institutions and local actors, recognising their key role in ensuring the effective implementation of the GHRI and in local ownership and adaptation to local realities, including through non-profit product development partnerships;

37. Calls on the Commission to strengthen coordination with Member States ahead of the replenishment of international health initiatives, working towards a joint replenishment figure and a coordinated, multi-year approach;

38. Calls on the Commission to improve the transparency, tracking and reporting of EU funding for global health, including under the Neighbourhood, Development and International Cooperation Instrument – Global Europe, by developing clear indicators to measure impact and effectiveness in terms of its contribution to strengthening health systems;

39. Highlights the unique value of global health initiatives; calls for the EU and its Member States to coordinate being represented on relevant governing boards and to participate actively in any review aimed at improving their efficiency and effectiveness;

Countering health disinformation and misinformation in partner countries

40. Calls on the Commission and the Member States to strengthen and coordinate their efforts to counter health misinformation, disinformation and foreign information manipulation in partner countries, to rebuild trust in evidence-based public health policies, and to improve health literacy and vaccine confidence;

41. Encourages the Commission to recognise the added value of digital public health tools alongside conventional medical countermeasures, particularly where they support decentralised surveillance, early warning, low-cost scalability, community engagement and timely public health decision-making, while ensuring strong safeguards on data protection, equity and local ownership;

Way forward and implementation

42. Calls on the Commission to present a clear roadmap and monitoring plan for implementing the communication entitled ‘Reinforcing global health resilience amidst geopolitical change’ and to report regularly to the Council and Parliament, including on the roll-out of the flagship initiatives included in the communication;

43. Notes that the GHRI aims to strengthen both EU and global health security through cooperation with partner countries; calls on the Commission to publish, as part of its implementation roadmap, a clear accountability framework setting out how each flagship initiative will respond to the needs and priorities of partner countries, in order to ensure mutual benefit and transparency in implementation; asks that this roadmap include measurable objectives, timelines, financial commitments, governance arrangements, partner-country ownership mechanisms, civil society participation and indicators to assess impact on equity, resilience, access and local capacity, as well as meaningful consultation of partner countries throughout the design, implementation and governance of the initiative;

44. Highlights the fact that the EU’s ambition to lead in global health must be backed by adequate, predictable and sustained financing for global health systems; stresses the need to include global health resilience as an objective under the next multiannual financial framework, with a clear budgetary allocation under relevant instruments such as the Global Europe instrument and Horizon Europe; calls for EU external action and research instruments to include clearly traceable funding for global health resilience;

45. Stresses that future financial commitments should be accompanied by clear objectives, measurable results and strong accountability mechanisms; reiterates that grant-based public funding remains indispensable for strengthening health systems and achieving equitable access to healthcare in partner countries, and that public financing should remain the foundation of EU support for global health resilience, while leveraging private investment and innovative financing instruments where appropriate;

°

° °

46. Instructs its President to forward this resolution to the Council, the Commission and the governments and parliaments of the Member States.